Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    GLP-1 drugs for employees cost $250M a year

    AdminBy AdminAugust 11, 2026 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    Bank of America CEO Brian Moynihan: We spend 'about $250 million or more' on GLP-1 drugs each year

    Bank of America spends more than $250 million a year covering GLP-1 weight loss drugs for its employees, CEO Brian Moynihan told CNBC on Wednesday, saying the rapidly rising cost is a worthwhile investment in his workforce.

    The company sets aside more than $2 billion a year on healthcare overall for BofA’s roughly 211,000 employees, meaning that GLP-1 medications alone now account for roughly 13% of all healthcare spending, per figures provided by Moynihan.

    “We spend about $250 million or more on GLPs, and that’s up from zero” four or five years ago, Moynihan told CNBC’s Andrew Ross Sorkin. “We see a great impact on the employees.”

    Employers across the country have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually. Many self-insured companies and public employers have dropped or restricted coverage or debated whether they can afford the treatments as utilization has climbed.

    Moynihan acknowledged that some employees may leave Bank of America before the company realizes the long-term savings from improved health, but he said the decision ultimately reflects a push to provide valuable benefits.

    Bank of America pairs access to the drugs with health coaching to help monitor weight loss and lifestyle adjustments, the CEO said. Beyond long-term preventative health, Moynihan pointed to emerging clinical data suggesting nearer-term benefits, including a lower incidence of cardiovascular events.

    “It’s been fascinating to watch our teammates’ behavior on these adjustments — the loss of weight,” he said.

    Costly coverage

    The nation’s second-largest lender by assets is also using its size to negotiate lower prices from drugmakers and pharmacy benefit managers, he said.

    “Believe me, we’re pounding everybody on price and trying to get as cheap [as possible],” Moynihan said. “But our view is that [because of] the long-term health benefits, plus there may be more short-term health benefits … it’s a good investment.”

    Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, according to a survey released in July by the International Foundation of Employee Benefit Plans, or IFEBP, which includes more than 30,000 member companies or public institutions.

    Though that percentage is up slightly from 34% in 2024, it’s flat from 2025, the survey found. 

    Cost remains a primary driver in employer decisions around GLP-1 coverage: In 2026, respondents to the IFEBP survey said the drugs accounted for 11.4% of annual claims, up from 6.9% in 2023.

    Obesity drugmakers Eli Lilly and Novo Nordisk have been pushing to boost employer coverage, which is key to unlocking greater uptake for their treatments. The discounted cash prices of those drugs, which are several hundred dollars a month depending on the dose, are still unsustainable for some patients.

    In March, Lilly launched a new program designed to give employers more flexibility in how they cover treatments. Through the effort, employers can pay a net discounted price of $449 per month for a new multi-dose form of Zepbound across all doses.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Holiday airfares hit highest levels in a decade as jet fuel prices surge

    November 21, 2026

    Over 314,000 older Toyota and Lexus vehicles recalled for potentially dangerous airbag issue

    November 20, 2026

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026
    Popular Posts

    Only the Seminole tribe can offer online gambling in Florida—and they're furious at DraftKings

    Steve Aoki tries to get a real job on LinkedIn, gives up two hours later, becomes thought leader

    What to Watch This Weekend, YA Edition

    Summer Survival Guide: Get Rid of All Types of Sweat Stains

    Are You Under Attack By Howard Bloom

    DOJ dropping Alaska midterms Senate certification lawsuit, saying case is 'moot'

    Categories
    • Books (2,460)
    • Business (3,451)
    • Events (34)
    • Film (1,066)
    • LifeStyle (2,925)
    • Music (2,800)
    • Politics (2,356)
    • Science (1,955)
    • Technology (1,820)
    • Television (3,632)
    • US News (3,296)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • 7 Poetry Collections About the Complexities of Black Womanhood 7 Poetry Collections About the Complexities of Black Womanhood 
    • 5 Best Carolina Herrera Colognes for Pulse-Point Perfection5 Best Carolina Herrera Colognes for Pulse-Point Perfection
    • Box Office: ‘Now You See Me 3’ Sprinting to Surprise $22M Win as ‘Running Man’ ChokesBox Office: ‘Now You See Me 3’ Sprinting to Surprise $22M Win as ‘Running Man’ Chokes
    • Kelley Flanagan Mourns Huge Loss On ChristmasKelley Flanagan Mourns Huge Loss On Christmas
    • TV Review: ‘Ted Lasso’ Season 4
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.